Twice-Yearly Lenacapavir or Daily F/TAF for HIV Prevention in Cisgender Women
Gilead Sciences
Linda-Gail Bekker; Moupali Das; Quarraisha Abdool Karim; Khatija Ahmed; Joanne Batting; William Brumskine; Katherine Gill; Ishana Harkoo; Manjeetha Jaggernath; Godfrey Kigozi; Noah Kiwanuka; Philip Kotze; Limakatso Lebina; Cheryl E Louw; Moelo Malahleha; Mmatsie Manentsa; Leila E Mansoor; Dhayendre Moodley; Vimla Naicker; Logashvari Naidoo; Megeshinee Naidoo; Gonasagrie Nair; Nkosiphile Ndlovu; Thesla Palanee-Phillips; Ravindre Panchia; Saresha Pillay; Disebo Potloane; Pearl Selepe; Nishanta Singh; Yashna Singh; Elizabeth Spooner; Amy M Ward; Zwelethu Zwane; Ramin Ebrahimi; Yang Zhao; Alexander Kintu; Chris Deaton; Christoph C Carter; Jared M Baeten; Flavia Matovu Kiweewa; PURPOSE 1 Study Team